Bryleos is a clinical-stage therapeutics company focused on revolutionizing the treatment of age-related diseases and enhancing longevity through a new class of oral NAD+ therapeutics. Their flagship product, BRY101, is an oral solid dose NAD+ therapeutic engineered to rapidly increase intracellular NAD, specifically targeting multifactorial neurological diseases. The company leverages cutting-edge technology to support optimal cell function, addressing the burden of expensive chronic illnesses.
Bryleos is a woman-owned and women-led organization committed to advancing the treatment of complex neurological conditions. The company has achieved significant milestones in developing its patent-pending oral NAD+ formulation, positioning itself as a leader in the field of innovative therapeutics. By moving beyond traditional single-target drug models, Bryleos aims to make a substantial impact on the healthcare landscape, particularly in the realm of neurological disease management.
